Table 3.
HCACi that are listed at clinicaltrials.gov, with at least one listed phase I clinical trial.
| Drug Type | Compound | Name | Selectivity | Clinical Status | Used in Myeloid Disease |
|---|---|---|---|---|---|
| Hydroxamates | MK0653 (SAHA) | Vorinostat | Pan HDACi | Phase II/III. Approved. |
Yes. Single and combination |
| LBH589 | Panobinostat | Pan HDACi | Phase II/III. Approved. |
Yes. Single and combination |
|
| PXD101 | Belinostat | Pan HDACi | Phase I/ II/III. Approved. |
Yes. Combination therapy |
|
| JNJ-26481585 | Quisinostat | HDAC1,3,5,8 | Phase I/II | MDS and AML. Single therapy |
|
| ITF2357 | Givinostat | Class I and II | Phase I/II | MPN. Single and combination |
|
| SB939 | Pracinostat | Class I, II, IV | Phase II | Yes. Single and combination |
|
| SHP141 | Remetinostat | Phase II/III | No | ||
| 4SC201 | Resminostat | Pan HDACi | Phase I/II | No | |
| 4SC202 | Domatinostat | HDAC1,2,3 | Phase I/II Approved in melanoma (combination) |
Yes. Single therapy |
|
| ACY1215 | Ricolinostat | HDAC6 | Phase I/II | No | |
| Cyclic tetrapeptides | FK228 | Romidepsin | Class I | Phase I/II/III. Approved. |
Yes. Single and combination |
| Benzamides | MS275 | Entinostat | HDAC1,2,3 | Phase I/II | Yes Combination therapy |
| MGCD0103 | Mocetinostat | Class I | Phase I/II | Yes Single and combination |
|
| Fatty acids | Valproic acid | Valproate | Class I and IIa | Phase I/ II | Yes Combination therapy |
| Sodium Butyrate | Butyrate | Class I and IIa | Phase I/II | Mostly non cancer diseases |